Pasar al contenido principal

Interacción de la inflamación del sistema nervioso periférico y central en la enfermedad de Alzheimer y el síndrome de Down

PI23/01786

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i en Salud
Año convocatoria 2023
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO
Centro realización IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO

Resultados relacionados

Resultados totales (Incluyendo duplicados): 27
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Plasma p-tau212 as a biomarker of sporadic and Down Syndrome Alzheimer's disease

  • Kac, Przemysław R.|||0000-0001-5083-0924
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Montoliu Gaya, Laia|||0000-0001-7684-6318
  • Fernández, Susana|||0000-0002-9777-1156
  • Lantero Rodríguez, Juan|||0000-0002-7426-678X
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • González-Ortiz, Fernando
  • Benejam, Bessy|||0000-0002-6789-8615
  • Turton, Michael
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Harrison, Peter
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Ashton, Nicholas J.|||0000-0002-3579-8804
  • Lleó, Alberto|||0000-0002-2568-5478
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Karikari, Thomas K.|||0000-0003-1422-4358
  • Fortea, Juan|||0000-0002-1340-638X
  • Blennow, Kaj|||0000-0002-1890-4193
All individuals with Down Syndrome (DS) will develop full-blown Alzheimeŕs disease (AD) pathology by age 40, decades before the occurrence of sporadic late-onset AD. Understanding this strong biological relation between age and AD pathology risk in DS is important to accelerate diagnostics, disease monitoring, and treatment. Several genes encoded in chromosome 21 including dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) have been proven to contribute to the pathology. A recently validated plasma immunoassay to measure tau phosphorylation at threonine-212 (p-tau212) has very high diagnostic accuracy in detecting AD. P-tau212 is also very sensitive to DYRK1A phosphorylation and is increased in DSAD brain lysates. Here, we assessed the potential of this biomarker in DSAD and sporadic AD. Using Simoa technology, we tested p-tau212 and p-tau181 (n=245 for plasma, n=114 matching cerebrospinal fluid (CSF) samples). We used AUC-ROC to examine diagnostic performance and the DeLong test to compare the AUC-ROC differences between methods. Spearman correlation is used to examine correlations. Fold changes relative to median levels were calculated for their respective asymptomatic groups. ANCOVA followed by Tukey posthoc test was used to calculate differences across groups. LOESS was used to determine the temporality of plasma biomarker changes. We have confirmed that p-tau212 has extremely high accuracy in detecting AD-related changes in euploid controls. For the DS population, we observed a strong correlation between plasma and CSF p-tau212 (r=0.867; p<0.001). In prodromal DS (pDS) and dementia DS (dDS), we observed significantly elevated levels of p-tau212 in reference to asymptomatic DS (aDS). The diagnostic accuracy to differentiate between aDS and dDS was AUC=0.91 and AUC = 0.86 in discriminating between DS amyloid positive and amyloid negative participants. Plasma p-tau212 started increasing approximately when people became amyloid PET-positive. We have confirmed that the levels of plasma p-tau212 are increased in the DS population and sporadic AD cases including prodromal and MCI states. Plasma p-tau212 might have utility for theragnostic, monitoring therapy efficacy, and as a target engagement biomarker in clinical trials both in sporadic and DSAD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Clinical and research application of fluid biomarkers in autosomal dominant Alzheimer's disease and Down syndrome

  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • O'Connor, A.
  • Llibre-Guerra, J.
  • Lao, P.|||0000-0003-2243-3547
  • Ashton, Nicholas J.|||0000-0002-3579-8804
  • Fortea, Juan|||0000-0002-1340-638X
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
Autosomal dominant Alzheimer's disease (ADAD) and Down syndrome (DS) constitute genetic forms of Alzheimer's disease (AD). The study of these forms has been crucial in understanding the biomarker changes and disease progression, notably in advancing our knowledge of the natural history of AD. However, some specific characteristics of biomarkers in genetically determined forms and, most importantly, the near full penetrance and predictability of disease onset lead to a very different context of use for biomarkers in these populations. This article delves into the similarities and differences in biomarker profiles between genetically determined AD and sporadic cases, discussing the implications for research and clinical practice. It also emphasizes the need to account for factors that may affect biomarker reliability differently in genetically determined AD. Enhancing our understanding of the disease will pave the way for more personalized therapeutic approaches for affected individuals.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Insights into the use of biomarkers in clinical trials in Alzheimer's disease

  • Pascoal, Tharick|||0000-0001-9057-8014
  • Aguzzoli, C.S.
  • Lussier, F.Z.
  • Crivelli, L.
  • Suemoto, C.K.|||0000-0002-5942-4778
  • Fortea, Juan|||0000-0002-1340-638X
  • Rosa-Neto, P.
  • Zimmer, E.R.
  • Ferreira, P.C.L.
  • Bellaver, B.|||0000-0002-2212-3373
Biomarkers have been instrumental in population selection and disease monitoring in clinical trials of recently FDA-approved drugs targeting amyloid-β to slow the progression of Alzheimer's disease (AD). As new therapeutic strategies and biomarker techniques emerge, the importance of biomarkers in drug development is growing exponentially. In this emerging landscape, biomarkers are expected to serve a wide range of contexts of use in clinical trials focusing on AD and related dementias. The joint FDA-NIH BEST (Biomarkers, EndpointS, and other Tools) framework provides standardised terminology to facilitate communication among stakeholders in this increasingly complex field. This review explores various applications of biomarkers relevant to AD clinical trials, using the BEST resource as a reference. For simplicity, we predominantly provide contextual characterizations of biomarkers use from the perspective of drugs targeting amyloid-β and tau proteins. However, general definitions and concepts can be extrapolated to other targets.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cerebrospinal fluid lipoprotein-mediated cholesterol delivery to neurons is impaired in Alzheimer's disease and involves APOE4

  • Borràs, Carla|||0000-0002-0998-7855
  • Canyelles, Marina|||0000-0002-0278-5337
  • Santos, David|||0000-0003-1157-4969
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Nuñez, Estefania|||0000-0002-0876-1264
  • Vázquez, Jesús|||0000-0003-1461-5092
  • Maspoch, Daniel|||0000-0003-1325-9161
  • Cano-Sarabia, Mary|||0000-0003-4254-8157
  • Zhao, Qi
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Sirisi Dolcet, Sonia|||0000-0002-5366-7832
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
In the central nervous system, apolipoprotein (APO)E-containing lipoprotein particles mediate the transport of glial-derived cholesterol to neurons, which is essential for neuronal membrane remodeling and maintenance of the myelin sheath. We aimed to examine cholesterol transport via lipoprotein particles in cerebrospinal fluid (CSF) of Alzheimer's disease (AD) patients compared to control individuals. Additionally, we explored the ability of reconstituted HDL containing different APOE isoforms to regulate cholesterol transport. We evaluated the capacity of CSF lipoprotein particles to facilitate radiolabeled unesterified cholesterol efflux from A172 human glioblastoma astrocytes and to deliver cholesterol to SH-SY5Y human neuronal cells. The CSF lipoprotein proteome was analyzed by LC-MS/MS. Reconstituted HDL nanoparticles were prepared by combining phospholipids and cholesterol with human APOE3 or APOE4, followed by radiolabeling with unesterified cholesterol. Our results showed that cholesterol efflux from astrocytes to CSF were similar between AD patients and controls, both under baseline conditions and after activation of ABCA1 and ABCG1. However, CSF lipoprotein-mediated neuronal cholesterol uptake was significantly reduced in the AD group. LC-MS/MS analysis identified 239 proteins associated with CSF lipoproteins in both groups, with no major alterations in proteins linked to cholesterol metabolism. However, 27 proteins involved in noncholesterol-related processes were differentially expressed. Notably, synthetic reconstituted HDL particles containing APOE4 exhibited reduced capacity to deliver cholesterol to neurons compared to those with APOE3. These findings indicate that CSF lipoproteins from patients with AD demonstrate impaired cholesterol delivery to neurons. Our study highlights APOE4 as a critical contributor to abnormal neuronal cholesterol uptake in AD pathophysiology.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Alpha-synuclein co-pathology in Down syndrome-associated Alzheimer's disease

  • Bernhardt, Alexander Maximilian
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Aldecoa, Iban|||0000-0001-5774-7453
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Arriola Infante, José Enrique|||0000-0002-3298-4601
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Longen, Sebastian
  • Trossbach, Svenja Verena
  • Giese, Armin
  • Matthias, Torsten
  • Benejam, Bessy|||0000-0002-6789-8615
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Hoyo Soriano, Laura del|||0000-0003-4372-1599
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Sanjuan, Aída
  • Fernández, Susana|||0000-0002-9777-1156
  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Aranha, Mateus|||0000-0001-9594-292X
  • Morcillo Nieto, Alejandra O.|||0000-0003-2202-3521
  • Nübling, Georg|||0000-0003-4492-7302
  • Wagemann, Olivia
  • Stockbauer, Anna
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Lleó, Alberto|||0000-0002-2568-5478
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Molina-Porcel, Laura|||0000-0003-4068-8578
  • Fortea, Juan|||0000-0002-1340-638X
  • Levin, Johannes|||0000-0001-5092-4306
Alpha-synuclein (αSyn) seed amplification assay (SAA) enables in vivo study of αSyn but remains underexplored in Down syndrome-associated Alzheimer's disease (DSAD). We analyzed αSyn-SAA in cerebrospinal fluid (CSF) from 270 adults with Down syndrome, from the Down Alzheimer Barcelona Neuroimaging Initiative and from the AD21 cohort from the Department of Neurology at the University Hospital, Ludwig Maximilian University of Munich, Germany. Neuropathological examinations were conducted in 19 brain donors (five with ante mortem CSF). Participants were classified as asymptomatic or symptomatic (prodromal/dementia) Alzheimer's disease (AD). CSF Aβ1-42/1-40, CSF and plasma p-Tau181, and neurofilament light chain (NfL) levels were measured. Neuropathological evaluations assessed AD neuropathological changes and Lewy body pathology (LBP). ΑSyn-SAA was positive in 9.2% of cases, independent of age or cognitive status. Symptomatic αSyn-positive cases exhibited higher plasma NfL levels than αSyn-negative cases (31 vs 21 pg/mL, p = 0.027). LBP was observed in 47% of necropsies. The individual with severe neocortical LBP was αSyn-SAA-positive. These findings highlight LBP prevalence in DSAD but suggest current SAA may fail to detect limited αSyn deposition.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Single-cell RNA sequencing highlights the role of distinct natural killer subsets in sporadic amyotrophic lateral sclerosis

  • Álvarez-Sánchez, Esther|||0009-0002-8760-2153
  • Carbayo Viejo, Álvaro|||0000-0001-9282-8603
  • Valle-Tamayo, Natalia|||0000-0001-9322-3710
  • Muñoz, Laia|||0000-0003-0578-3094
  • Aumatell Escabias, Joaquim
  • Torres Alcalá, Soraya|||0000-0002-7054-2046
  • Rubio Guerra, Sara|||0000-0001-7652-8029
  • Garcia Castro, Jesús|||0000-0003-1503-4775
  • Selma Gonzalez, Judit|||0009-0006-1021-4653
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Lleó, Alberto|||0000-0002-2568-5478
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Fortea, Juan|||0000-0002-1340-638X
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Dols Icardo, Oriol|||0000-0003-2656-8748
Neuroinflammation plays a major role in amyotrophic lateral sclerosis (ALS), and cumulative evidence suggests that systemic inflammation and the infiltration of immune cells into the brain contribute to this process. However, no study has investigated the role of peripheral blood immune cells in ALS pathophysiology using single-cell RNA sequencing (scRNAseq). We aimed to characterize immune cells from blood and identify ALS-related immune alterations at single-cell resolution. For this purpose, peripheral blood mononuclear cells (PBMC) were isolated from 14 ALS patients and 14 cognitively unimpaired healthy individuals (HC), matched by age and gender, and cryopreserved until library preparation and scRNAseq. We analyzed differences in the proportions of PBMC, gene expression, and cell-cell communication patterns between ALS patients and HC, as well as their association with plasma neurofilament light (NfL) concentrations, a surrogate biomarker for neurodegeneration. Flow cytometry was used to validate alterations in cell type proportions. We identified the expansion of CD56 dim natural killer (NK) cells in ALS (fold change = 2; adj. p -value = 0.0051), mainly driven by a specific subpopulation, NK_2 cells (fold change = 3.12; adj. p -value = 0.0001), which represent a mature and cytotoxic CD56 dim NK subset. Our results revealed extensive gene expression alterations in NK_2 cells, pointing towards the activation of immune response (adj. p -value = 9.2 × 10 - 11) and the regulation of lymphocyte proliferation (adj. p -value = 6.46 × 10 - 6). We also identified gene expression changes in other immune cells, such as classical monocytes, and distinct CD8 + effector memory T cells which suggested enhanced antigen presentation via major histocompatibility class-II (adj. p -value = 1.23 × 10 - 8) in ALS. The inference of cell-cell communication patterns demonstrated that the interaction between HLA-E and CD94:NKG2C from different lymphocytes to NK_2 cells is unique to ALS blood compared to HC. Finally, regression analysis revealed that the proportion of CD56 bright NK cells along with the ALSFRS-r, disease duration, and gender, explained up to 76.4% of the variance in plasma NfL levels. Our results reveal a signature of relevant changes occurring in peripheral blood immune cells in ALS and underscore alterations in the proportion, gene expression, and signaling patterns of a cytotoxic and terminally differentiated CD56 dim NK subpopulation (NK_2), as well as a possible role of CD56 bright NK cells in neurodegeneration. The online version contains supplementary material available at 10.1186/s12974-025-03347-0.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Comparison of the amyloid plaque proteome in Down syndrome, early-onset Alzheimer's disease, and late-onset Alzheimer's disease

  • Martá-Ariza, M.
  • Leitner, D.F.
  • Kanshin, E.
  • Suazo, J.
  • Giusti Pedrosa, A.
  • Thierry, M.
  • Lee, E.B.
  • Devinsky, O.
  • Drummond, E.
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Ueberheide, B.
  • Wisniewski, Thomas M.
Down syndrome (DS) is strongly associated with Alzheimer's disease (AD) due to APP overexpression, exhibiting Amyloid-β (Aβ) and Tau pathology similar to early-onset (EOAD) and late-onset AD (LOAD). We evaluated the Aβ plaque proteome of DS, EOAD, and LOAD using unbiased localized proteomics on post-mortem paraffin-embedded tissues from four cohorts (n = 20/group): DS (59.8 ± 4.99 y/o), EOAD (63 ± 4.07 y/o), LOAD (82.1 ± 6.37 y/o), and controls (66.4 ± 13.04). We identified differentially abundant proteins when comparing Aβ plaques and neighboring non-plaque tissue (FDR < 5%, fold-change.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Validation of the CAMCOG-DS-II, a neuropsychological test battery for Alzheimer's disease in people with Down syndrome, A Horizon 21 European Down syndrome Consortium study

  • Ivain, P.|||0000-0001-5302-1639
  • Baksh, A.
  • Saini, F.
  • Idris, M.
  • Tamayo-Elizalde, M.
  • Wells, J.
  • Benejam, Bessy|||0000-0002-6789-8615
  • Loosli, S.V.
  • Sandkühler, Katja|||0009-0000-7117-2270
  • Wlasich, E.
  • Wagemann, O.
  • Levin, J.
  • Martet, D.
  • Sacco, Simona|||0000-0003-0651-1939
  • Falquero, S.
  • Clert, M.
  • Rebillat, Anne-Sophie|||0000-0003-1995-9177
  • Khoo, W.M.
  • Smith, M.A.
  • Beresford-Webb, J.
  • Zaman, Shahid
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Fortea, Juan|||0000-0002-1340-638X
  • Langballe, E.M.
  • Medbøen, I.T.
  • Larsen, F.K.
  • Baldimtsi, E.
  • Paradisi, R.
  • Ntailakis, P.
  • Tsolaki, Magda|||0000-0002-2072-8010
  • Papantoniou, G.
  • McGlinchey, E.
  • McCarron, M.
  • Kennelly, S.
  • Strydom, A.
INTRODUCTION: The Cambridge Cognitive Examination modified for use in people with Down syndrome (CAMCOG-DS) is a sensitive cognitive test for Alzheimer's disease (AD)-related decline in people with DS, but needs updates for sensitivity, cultural adaptability, and additional memory/executive function items. This study aimed to develop and validate the CAMCOG-DS-II. METHODS: In this multi-language, multi-site study, the psychometric properties of the CAMCOG-DS-II were evaluated against previously validated measures in 223 participants (mean age: 40.18 years) with DS across seven countries. RESULTS: The CAMCOG-DS-II had a high completion rate, minimal floor/ceiling effects (compared to the modified Cued Recall Test, the CANTAB Paired Associates Learning, and the Purdue Pegboard), strong validity and reliability, and performance was unaffected by language across sites. It differentiated between those with/without AD and distinguished clinically rated cognitively stable and prodromal individuals. CONCLUSION: The CAMCOG-DS-II is a sensitive measure of cognitive performance in people with DS at risk of AD. Its cross-language and site reliability support its potential use in AD-DS clinical trials. Highlights: Developed and validated the Cambridge Cognitive Examination modified for use in people with Down syndrome (CAMCOG-DS-II) for Alzheimer's disease in Down syndrome. CAMCOG-DS-II shows increased sensitivity to Alzheimer's disease-related decline in Down syndrome. Improved applicability across an international and culturally diverse population. Differentiates Alzheimer's disease status: cognitively stable, prodromal, and clinical.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Exploratory analysis of the proteomic profile in plasma in adults with Down syndrome in the context of Alzheimer's disease

  • Wagemann, O.
  • Nübling, G.
  • Martínez-Murcia, F.J.
  • Wlasich, E.
  • Loosli, S.V.
  • Sandkühler, Katja|||0009-0000-7117-2270
  • Stockbauer, A.
  • Prix, C.
  • Katzdobler, S.
  • Petrera, A.
  • Hauck, S.M.
  • Fortea, Juan|||0000-0002-1340-638X
  • Romero-Zaliz, R.
  • Jiménez-Mesa, C.
  • Górriz Sáez, J.M.
  • Höglinger, G.
  • Levin, J.
INTRODUCTION: Adults with Down syndrome (DS) show increased risk for Alzheimer's disease (AD) due to the triplication of chromosome 21 encoding the amyloid precursor protein gene. Further, this triplication possibly contributes to dysregulation of the immune system, furthering AD pathophysiology. METHODS: Using Olink Explore 3072, we measured ∼3000 proteins in plasma from 73 adults with DS and 15 euploid, healthy controls (HC). Analyses for differentially expressed proteins (DEP) were carried out, and pathway and protein network enrichment using Gene Ontology, Kyoto Encyclopedia of Genes and Genomes (KEGG), and STRING database was investigated. Within DS, the LASSO (least absolute shrinkage and selection operator) feature selection was applied. RESULTS: We identified 253 DEP between DS and HC and 142 DEP between symptomatic and asymptomatic DS. Several pathways regarding inflammatory and neurodevelopmental processes were dysregulated in both analyses. LASSO feature selection within DS returned 15 proteins as potential blood markers. DISCUSSION: This exploratory proteomic analysis found potential new blood biomarkers for diagnosing DS-AD in need of further investigation. Highlights: Inflammatory pathways are dysregulated in symptomatic versus asymptomatic DS. NFL and GFAP are confirmed as powerful biomarkers in DS with clinical and/or cognitive decline. Further circulating proteins were identified as potential blood biomarkers for symptomatic DS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Generational effects in Down syndrome, Enriched environment enhances functionality without reducing Alzheimer's disease risk

  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Benejam, Bessy|||0000-0002-6789-8615
  • Hoyo Soriano, Laura del|||0000-0003-4372-1599
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Fernández, Susana|||0000-0002-9777-1156
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Arriola Infante, José Enrique|||0000-0002-3298-4601
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Sanjuan, Aída
  • Morcillo Nieto, Alejandra O.|||0000-0003-2202-3521
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Arenaza-Urquijo, Eider|||0000-0001-7016-7576
  • Lleó, Alberto|||0000-0002-2568-5478
  • Bartrés-Faz, David|||0000-0001-6020-4118
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Fortea, Juan|||0000-0002-1340-638X
Down syndrome (DS) is the leading cause of intellectual disability (ID) and a genetic form of Alzheimer's disease (AD). We wanted to assess whether generational changes have induced (1) milder ID with greater independence and (2) delayed AD diagnosis. We analyzed 681 asymptomatic DS to test generational effects on ID, functionality, and cognition. In 353 DS individuals with AD, we compared clinical diagnosis age by ID using analysis of variance. In addition, dementia diagnosis age was examined through a published meta-analysis. Our results indicate a generational shift toward a higher proportion of individuals with mild/moderate ID, greater intelligence, and autonomy. However, it was not paralleled by an ID-related delay in the age at AD onset in our cohort, or by generational delays reported over the past 35 years. The findings highlight notable generational improvements in DS, but no effects on the age at AD dementia diagnosis. OrderedDict([(u'list', OrderedDict([(u'@list-type', u'bullet'), (u'@id', u'alz70447-list-0001'), (u'list-item', [OrderedDict([(u'p', u'A generational effect has reduced the severity of intellectual disability in Down syndrome (DS).')]), OrderedDict([(u'p', u'Individuals with DS have increased autonomy and improved intellectual milestones.')]), OrderedDict([(u'p', u"The enriched environment has not delayed the age at Alzheimer's disease (AD) dementia in DS.")]), OrderedDict([(u'p', u'Further studies should confirm if cognitive reserve might delay AD in DS.'.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Nerve growth factor precursor alterations in neuron-derived extracellular vesicles from individuals with Down syndrome along the Alzheimer's disease continuum

  • Valle-Tamayo, Natalia|||0000-0001-9322-3710
  • Aranha, Mateus|||0000-0001-9594-292X
  • Pérez-González, R.
  • Serrano-Requena, S.
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Benejam, Bessy|||0000-0002-6789-8615
  • Chiva-Blanch, Gemma|||0000-0001-6093-0160
  • Jiménez Pineda, Amanda|||0000-0003-4967-1174
  • Busciglio, J.
  • Wisniewski, Thomas M.
  • Carmo, S.D.
  • Álvarez-Sánchez, Esther|||0009-0002-8760-2153
  • Muñoz, L.
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Belbin, Olivia|||0000-0002-6109-6371
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Lleó, Alberto|||0000-0002-2568-5478
  • Cuello, AC.|||0000-0003-2143-2745
  • Fortea, Juan|||0000-0002-1340-638X
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Iulita, M. Florencia|||0000-0002-3360-4498
BACKGROUND: In Down syndrome (DS) and Alzheimer's disease (AD), nerve growth factor precursor protein (proNGF) accumulates in the brain. However, its non-invasive detection using neuron-derived extracellular vesicles (NDEVs) from plasma remains unexplored. METHODS: We included 139 adults with DS (45 asymptomatic [aDS], 94 symptomatic for AD [sDS]) and 37 healthy controls. NDEVs were isolated from plasma. ProNGF and tetraspanin (CD81) were quantified by enzyme-linked immunosorbent assay. We assessed proNGF/CD81 changes with age, along the AD continuum (aDS and sDS), and associations with cerebrospinal fluid (CSF), plasma biomarkers, episodic memory, and basal forebrain volume. RESULTS: In DS, proNGF/CD81 levels increased with age and were higher in NDEVs from asymptomatic and symptomatic individuals compared to controls, with the highest levels in the symptomatic group. ProNGF correlated with CSF phosphorylated tau (p-tau)181, plasma p-tau217, neurofilament light chain, and episodic memory. DISCUSSION: ProNGF/CD81 levels in NDEVs increase along the AD continuum in DS and parallel tau pathology, indicating the potential as a promising biomarker for monitoring disease progression in plasma. Highlights: Nerve growth factor precursor protein (ProNGF)/tetraspanin (CD81) ratio increased in the third decade of life, 20 years before Alzheimer's disease (AD) symptom onset in Down syndrome (DS). proNGF/CD81 concentrations were significantly higher in individuals with DS compared to controls and were notably elevated in individuals with DS and symptomatic AD compared to asymptomatic AD. proNGF/CD81 concentrations were associated with tau pathology and neuronal injury.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Sex differences in the executive and behavioral reserve of autosomal dominant frontotemporal dementia

  • Garcia Castro, Jesús|||0000-0003-1503-4775
  • Rubio Guerra, Sara|||0000-0001-7652-8029
  • Casaletto, Kaitlin B.
  • Selma Gonzalez, Judit|||0009-0006-1021-4653
  • Memel, M.|||0000-0001-6827-6335
  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Morcillo Nieto, Alejandra O.|||0000-0003-2202-3521
  • Arriola Infante, José Enrique|||0000-0002-3298-4601
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Belbin, Olivia|||0000-0002-6109-6371
  • Fortea, Juan|||0000-0002-1340-638X
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Sala Matavera, Isabel|||0000-0002-9886-4792
  • Heuer, H.W.
  • Forsberg, L.K.
  • Kantarci, K.
  • Staffaroni, Adam M.
  • Tartaglia, C.
  • Rankin, K.P.
  • Boeve, Bradley
  • Boxer, A.
  • Rosen, H.J.
  • Lleó, Alberto|||0000-0002-2568-5478
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
INTRODUCTION: Self-reported sex influences brain resilience, but its role in genetic frontotemporal dementia (FTD) remains unclear. METHODS: We analyzed 394 genetic-FTD patients and 279 controls from the ALLFTD consortium, assessing annual neuropsychological performance and MRI-based cortical thickness. Clinical characteristics and cortical thickness were compared between sexes. We used the residuals of linear regression models, which predict each participant's cognitive and behavioral performance levels relative to cortical thickness, as a proxy for reserve. We then modeled sex differences in longitudinal trajectories with linear mixed-effects models. RESULTS: Symptomatic females with genetic FTD had lower frontal cortical thickness than males, and the C9orf72 subgroup showed lower-than-expected frontal cortical thickness for a given level of executive functioning. Differences in cognitive reserve between sexes peaked near symptom onset but diminished thereafter. DISCUSSION: Females with genetic FTD showed higher cognitive reserve than males, suggesting that self-reported sex modulates resilience to frontotemporal neurodegeneration. Highlights: Females with genetic FTD showed higher cognitive reserve than males. Those differences were particularly pronounced in the C9orf72 and GRN subgroups. The higher cognitive reserve in females declined as the disease progressed.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Impact of Alzheimer's disease on sleep in adults with Down syndrome

  • Giménez, Sandra|||0000-0001-8031-2319
  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Zhu, Nuole|||0000-0002-0015-9455
  • Benejam, Bessy|||0000-0002-6789-8615
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Rebillat, Anne-Sophie|||0000-0003-1995-9177
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Arriola Infante, José Enrique|||0000-0002-3298-4601
  • Bueno-López, Ana|||0000-0003-2390-219X
  • Fernández, Susana|||0000-0002-9777-1156
  • Ribas, Laia
  • Zsadanyi, Sara E.|||0000-0002-2033-5989
  • Morcillo Nieto, Alejandra O.|||0000-0003-2202-3521
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Lisgaras, Christos Panagiotis
  • Blessing, Esther
  • Osorio, Ricardo S.
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
INTRODUCTION: Down syndrome (DS) is a genetic form of Alzheimer's disease (AD), with a high prevalence of sleep disorders, but data in adults with DS and dementia are lacking. We aim to assess sleep in adults with DS across the AD continuum. METHODS: We studied 78 healthy controls and 229 adults with DS (154 asymptomatic, 25 with prodromal AD, and 75 with AD) with subjective sleep measures and objective nocturnal polysomnography. RESULTS: Adults with DS presented worse sleep quality and higher prevalence of unnoticed obstructive sleep apnea (OSA) than controls. Sleep disruption and OSA severity increased across the AD continuum. Age-related decreases in slow-wave sleep and rapid eye movement sleep were more pronounced in the DS group. Subjective sleep measures did not capture sleep disorders. CONCLUSIONS: In DS, AD is linked to worse sleep disturbances and altered architecture. However, longitudinal studies are needed to clarify directionality and disease progression. Highlights: Down syndrome (DS) is associated with increased slow-wave sleep (SWS) and reduced rapid eye movement (REM) sleep. Obstructive sleep apnea prevalence increases along the Alzheimer's disease continuum in DS. Age-related decreases in SWS and REM sleep are accelerated in DS. Subjective sleep measures do not detect sleep disturbances in adults with DS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Plasma p-tau212 as a biomarker of sporadic and Down syndrome Alzheimer's disease

  • Kac, Przemysław R.|||0000-0001-5083-0924
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Montoliu Gaya, Laia|||0000-0001-7684-6318
  • Fernández, S.
  • Lantero Rodríguez, Juan|||0000-0002-7426-678X
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • González-Ortiz, F.
  • Benejam, Bessy|||0000-0002-6789-8615
  • Turton, M.
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Harrison, P.
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Ashton, Nicholas J.|||0000-0002-3579-8804
  • Lleó, Alberto|||0000-0002-2568-5478
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Karikari, Thomas K.|||0000-0003-1422-4358
  • Fortea, Juan|||0000-0002-1340-638X
  • Blennow, Kaj|||0000-0002-1890-4193
BACKGROUND: All individuals with Down syndrome (DS) will develop full-blown Alzheimer's disease (AD) pathology by age 40. Several genes encoded in chromosome 21, including dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A), have been proven to contribute to the pathology. Phosphorylation of tau at threonine-212 (p-tau212) is very sensitive to DYRK1A phosphorylation and is increased in DSAD brain lysates. Here, we assessed the potential of this biomarker in DSAD and sporadic AD. METHODS: Using single molecule array (Simoa) technology, we tested p-tau212 and p-tau181 (n = 245 for plasma, n = 114 matching cerebrospinal fluid [CSF] samples). RESULTS: We have confirmed that the levels of plasma p-tau212 are increased in the DS population and sporadic AD cases, including prodromal and mild cognitive impairment states. Plasma p-tau212 started increasing approximately when people became amyloid positron emission tomography positive. DISCUSSION: Plasma p-tau212 might have utility for theragnostics, monitoring therapy efficacy, and as a target engagement biomarker in clinical trials both in sporadic and DSAD. Highlights: Plasma p-tau212 is increased in the Down syndrome (DS) population. Plasma p-tau212 increases ≈15 years before the disease onset in DSAD. Plasma p-tau212 accurately differentiates between control and disease groups. Plasma p-tau212 accurately differentiates amyloid beta (Aβ)+ and Aβ- participants.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Bridging perspectives, The value of collaboration between Traditional Healing Practitioners and Medical Doctors in dementia research and care in South Africa

  • McGlinchey, E.
  • Ranchod, K.
  • Stroebel, R.
  • Lusizi, B.
  • Galvin, M.
  • Kleinhans, A.V.
  • Fortea, Juan|||0000-0002-1340-638X
  • Hoffman, J.
  • Makanya, S.
INTRODUCTION: Traditional Healing Practitioners (THPs) provide care to the majority of the population in South Africa. Despite their widespread presence, they remain largely excluded from dementia research and policy. This reinforces healthcare inequities and overlooks the realities of communities where THPs provide care. METHODS: This paper explores the role of THPs in dementia care by examining literature in South Africa. It identifies key barriers to collaboration between THPs and medical doctors and discusses pathways for integration. RESULTS: Barriers include epistemological historical marginalization, mutual distrust, fragmented care pathways, and language barriers. These challenges hinder knowledge exchange and joint dementia care strategies. DISCUSSION: Strengthening relationships through structured engagement, bidirectional knowledge exchange, and ethical collaboration could bridge the gap between THPs and Medical Doctors (MDs). A pluralistic, integrated model valuing both systems could lead to more equitable and effective dementia care. Highlights: The majority of people in South Africa engage with Traditional Healing Practitioners (THPs) as part of their healthcare, yet THPs remain largely excluded from dementia research and policy. Barriers to collaboration between THPs and Medical Doctors (MDs) include historical marginalization, mutual distrust, fragmented care pathways, and language differences. Integrating THPs and MDs through structured engagement, bidirectional knowledge exchange, and ethical collaboration could enhance dementia care. Shifting away from the binary opposition of Indigenous Knowledge Systems (IKS) and biomedical approaches toward a more integrated and collaborative model of dementia care could lead to more equitable and effective healthcare. The FUNDISA (Framework for Understanding Neurocognitive Disorders via Indigenous Systems in South Africa) project aims to understand how dementia is conceptualized by THPs and foster collaboration between THPs and MDs to support effective dementia care.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Discrepancies in assessing intellectual disability levels in adults with Down syndrome, Implications for dementia diagnosis

  • Hoyo Soriano, Laura del|||0000-0003-4372-1599
  • Sandkühler, Katja|||0009-0000-7117-2270
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Benejam, Bessy|||0000-0002-6789-8615
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Wlasich, E.
  • Kustermann, J.
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Fernández, Susana|||0000-0002-9777-1156
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Arriola Infante, José Enrique|||0000-0002-3298-4601
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • San Juan, Aida
  • Nübling, G.
  • Wagemann, O.
  • Stockbauer, A.
  • Hassenstab, J.
  • Levin, J.
  • Fortea, Juan|||0000-0002-1340-638X
INTRODUCTION: Cut-offs derived from baseline cognitive assessments, stratified by intellectual disability (ID) level, have been proposed to diagnose symptomatic Alzheimer's disease (AD) in Down syndrome (DS). However, discrepancies in ID classification risk misclassification when applying cut-offs across sites. METHODS: This dual-center cohort study included 673 adults with mild to moderate ID at different AD stages. We assessed ID classification discrepancies across sites and the impact on Cambridge Cognitive Examination for Older Adults with Down's Syndrome (CAMCOG-DS) cut-offs for AD dementia diagnosis derived from receiver operating characteristic analysis. RESULTS: Inter-rater agreement for ID level classification was 95% within sites but 60% between sites. While CAMCOG-DS score distributions in the whole cohort were similar across sites, ID classification discrepancies caused higher cut-offs in Barcelona for mild and moderate ID compared to Munich. Applying site-specific cut-offs to another cohort reduced sensitivity and specificity. DISCUSSION: Standardizing ID classification is critical for generalizable cut-offs to accurately diagnose AD dementia based on neuropsychological assessments in DS. Highlights: CAMCOG-DS cut-offs by intellectual disability level classify dementia in Down syndrome. ID classification discrepancies between sites impact CAMCOG-DS diagnostic cut-offs. Applying site-specific cut-offs to other cohorts reduces sensitivity and specificity. Standardized ID classification is essential for generalizable cognitive cut-offs. Use site-specific cut-offs until ID classification is standardized.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cargo of small extracellular vesicles from neuronal origin shows progression of dementia in individuals with Down syndrome

  • Ledreux, A.|||0000-0001-6232-7672
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Benejam, Bessy|||0000-0002-6789-8615
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Lleó, Alberto|||0000-0002-2568-5478
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Fortea, Juan|||0000-0002-1340-638X
INTRODUCTION: Individuals with Down syndrome (DS) are at an ultra-high risk of developing Alzheimer's disease (AD). Diagnosis of AD onset in people with DS can be challenging due to the variable degrees of intellectual disability and cognitive impairment among individuals. METHODS: Plasma samples from individuals with DS diagnosed with AD dementia (n = 33), prodromal AD (n = 31), or cognitively stable (n = 43) were enriched for neuron-derived extracellular vesicles (NDEV) using immunocapture with the L1CAM antibody. We used single-molecule array technology to quantify amyloid-β (Aβ) peptides, Tau, phosphorylated Tau, neurofilament light chain (NfL), and synaptosomal-associated protein 25 (SNAP25) across diagnostic groups. RESULTS: NDEV levels of Aβ40, Aβ42, Tau, pTauT181, pTauT231, NfL, and SNAP25 were significantly higher in people with DS diagnosed with prodromal AD compared to those with no cognitive decline. Middle-aged or older women had higher levels of NDEV biomarkers compared to males. DISCUSSION: NDEV biomarker levels can inform on the onset of AD in individuals with DS. Highlights: Diagnosis of Alzheimer's dementia in individuals with Down syndrome (DS)is challenging. Neuron-derived extracellular vesicles were enriched from plasma of adults with Down syndrome. Alzheimer's disease biomarkers were measured using single molecule array technology. NDEV biomarkers accurately predicted the prodromal stage of dementia in people with DS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Down syndrome in Africa, Challenges, opportunities, and future directions

  • McGlinchey, E.
  • Tewolde, S.
  • He, A.
  • Fortea, Juan|||0000-0002-1340-638X
  • Mbakile-Mahlanza, L.
  • Tefera, A.
  • Epenge, E.
  • Hassenstab, J.
  • Jäck, A.
  • Ranchod, K.
  • El-Jaafary, S.
  • Levin, J.
  • Salama, M.
  • Rubenstein, E.
  • Akinyemi, R.
  • Akinyemi, T.
  • Farombi, T.
  • Lawlor, B.
  • Ikanga, J.
  • Ashton, Nicholas J.|||0000-0002-3579-8804
  • Stout, S.
  • Balls-Berry, J.
  • Kleinhans, A.V.
  • Maina, R.
  • Merali, Z.
INTRODUCTION: As life expectancy improves for people with Down syndrome (DS) in Africa, the risk of developing DS-associated Alzheimer's disease (DSAD) will rise. There is a pressing need to plan for this emerging challenge, particularly in the context of existing health and social disparities. METHODS: This work emerged from a pan-African collaboration, including discussions at the Brain Ageing and Dementia in Low- and Middle-Income Countries conference held in Nairobi in 2024, where stakeholders identified regional priorities for DS and dementia care. RESULTS: Limited epidemiological, cognitive, biomarker data, delayed diagnoses, and gaps in specialized services may impact access to care. However, innovative solutions, such as mobile biomarker sampling and culturally adapted cognitive assessments, offer promising strategies. DISCUSSION: Integrating global advances in DSAD research with Africa's strengths in community-based care offers opportunities. By prioritizing research, capacity building, and health system integration, this work advocates for the inclusion of DS in Africa's dementia strategies. Highlights: Projected increases in life expectancy for individuals with Down syndrome (DS) in Africa will lead to a substantial rise in DS-associated Alzheimer's disease (DSAD), necessitating urgent planning and response. There is a critical lack of epidemiological, cognitive, and biomarker data on adults with DS in Africa, hindering accurate diagnosis, care planning, and inclusion in global research. Innovative, scalable solutions-such as mobile biomarker sampling and culturally adapted cognitive assessments-offer an opportunity to integrate scientific advances with Africa's strengths in community-based care. Investment in research and capacity building is essential to address current gaps, reduce disparities, and ensure equitable access to emerging diagnostics and treatments for DSAD across the continent.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Development of amyloid-negative neuropsychological norms using GAMLSS

  • Rubio Guerra, Sara|||0000-0001-7652-8029
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Sala Matavera, Isabel|||0000-0002-9886-4792
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Estanga, Ainara|||0000-0002-6616-314X
  • Ecay-Torres, Mirian|||0000-0001-7170-6180
  • de Luis, C.L.
  • Rami Gonzalez, Lorena|||0000-0002-7411-1921
  • Tort-Merino, Adrià|||0000-0002-5646-0482
  • Castellví, Magdalena|||0000-0001-8769-9288
  • Pozueta, A.
  • García-Martínez, M.
  • Gómez-Andrés, David|||0000-0001-5654-7791
  • Lage, Carmen|||0000-0003-1703-121X
  • López-Garcia, Sara
  • Sánchez-Juan, Pascual|||0000-0002-6081-8037
  • Balasa, Mircea|||0000-0002-1795-4228
  • Llado Plarrumani, Albert|||0000-0002-5066-4150
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Tainta, Mikel|||0000-0003-0624-1211
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Zhu, Nuole|||0000-0002-0015-9455
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Rodríguez-Rodríguez, Eloy|||0000-0001-7742-677X
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Martinez-Lage, Pablo|||0000-0001-5404-9967
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
INTRODUCTION: Recent research has suggested increased sensitivity of Alzheimer's disease (AD)-negative neuropsychological norms; concurrently, generalized additive models for location, scale, and shape (GAMLSS) have emerged as a promising alternative to traditional norming approaches. Here, we developed amyloid β-negative (Aβ-) next-generation norms (NGN) for a comprehensive neuropsychological battery using GAMLSS. METHODS: We included N = 987 cognitively normal (CN) individuals from a Spanish multicenter study with extensive neuropsychological data and cerebrospinal fluid AD biomarker assessment. NGN were developed using GAMLSS based on the performance of n = 774 Aβ- CN individuals aged 30-90 years. RESULTS: Age-, education-, and sex-adjusted z-scores were obtained for 14 measures covering the main cognitive domains (memory, language, attention/executive, and visuospatial functions). A user-friendly calculator for the z-scores was made available in an open-access ShinyApp to facilitate their application. DISCUSSION: NGN may improve the detection of objective cognitive impairment in clinical and research settings. Highlights: Brain amyloid β (Aβ) is associated with poorer performance in cognitively normal individuals. We provide GAMLSS-based Aβ-negative norms for 14 neuropsychological measures. Age, education, and often sex significantly influence cognitive performance. An online calculator for the demographically adjusted z-scores is freely available.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Prospective evaluation of plasma pTau217 stability for the detection of Alzheimer's disease in a tertiary memory clinic

  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Ferrer Pérez, Rosa|||0009-0004-9477-699X
  • Zhu, Nuole|||0000-0002-0015-9455
  • Rubio Guerra, Sara|||0000-0001-7652-8029
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Arriola-Infante, J.E.
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Garcia Castro, Jesús|||0000-0003-1503-4775
  • Selma Gonzalez, Judit|||0009-0006-1021-4653
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Alcolea, Daniel|||0000-0002-3819-3245
Background: Knowledge on the effect of analytical variability and storage conditions are essential for the successful implementation of plasma pTau in prospective settings. Aims: To investigate the performance of plasma pTau, measured in consecutive samples with LUMIPULSE, for detecting Alzheimer's disease in a prospective memory clinic setting, along with evaluating its pre-analytical and analytical stability. Methods: We prospectively measured pTau using the LUMIPULSE automated platform in consecutive patient plasma samples collected between May and November 2024 at the Sant Pau Memory Unit (Barcelona). A subset of participants also underwent paired lumbar puncture for CSF AD biomarkers. We compared biomarker concentrations under different short-term storage conditions (4ºC vs -20ºC) and different protocol pipelines, and assessed lot-to-lot variability. In the subset with available CSF biomarkers, logistic regression was used to evaluate the association between plasma pTau217 and the likelihood of a positive (A +) or a negative (A-) CSF amyloid status. Using ROC analysis, in this prospective cohort we evaluated the accuracy of previously established thresholds derived from historical samples. Results: We included 280 participants, divided into two groups: those with (n = 109) and without CSF data (n = 171). Among the subset with CSF, 48% were A +, with a plasma pTau fold-change of 4.5 × compared to A-. We found no differences in plasma pTau concentrations between either short-term storage conditions. The overall coefficients of analytical variation ranged from 1.8% to 3.2%. Plasma pTau concentrations were slightly higher in paired samples of the clinical protocol. Following a two-threshold approach, the need of confirmatory tests (grey zones) after measuring plasma pTau ranged between 45.9% and 18.3% using our previously reported strict or lenient cutoffs (overall accuracy 96.6% and 92.1%, respectively). Conclusions: The robust stability and low lot-to-lot variability of plasma pTau measurement in an automated platform result in high diagnostic performance of this biomarker in the prospective evaluation of patients in a memory clinic setting. These findings support its implementation into clinical routine, offering clinicians an accessible biomarker for AD diagnosis.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Plasma p-tau217 as a biomarker of Alzheimer's disease pathology in individuals with Down syndrome

  • Huber, H.
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Arslan, Burak
  • Leuzy, Antoine
  • Kittel, Oscar
  • Molfetta, Guglielmo Di
  • Benejam, Bessy|||0000-0002-6789-8615
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Hoyo Soriano, Laura del|||0000-0003-4372-1599
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Arriola Infante, José Enrique|||0000-0002-3298-4601
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Montoliu Gaya, Laia|||0000-0001-7684-6318
  • Lleó, Alberto|||0000-0002-2568-5478
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Blennow, Kaj|||0000-0002-1890-4193
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Fortea, Juan|||0000-0002-1340-638X
  • Ashton, Nicholas J.|||0000-0002-3579-8804
Diagnosing Alzheimer's disease (AD) in adults with Down syndrome (DS), a population with a high genetically determined risk of AD, remains challenging. In this large observational study including n = 2329 samples from the Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) and euploid controls from the Sant Pau Initiative on Neurodegeneration (SPIN) with and without symptomatic AD, we investigate if the strong diagnostic performance of plasma p-tau217 observed in sporadic AD extends to the DS population. Plasma p-tau217 discriminated cognitively stable individuals with DS from those with AD dementia with an AUC of 0.96 (95% CI, 0.95-0.97), and from those with prodromal AD with an AUC of 0.90 (95% CI, 0.87-0.92). Amyloid β (Aβ) positive and Aβ negative individuals with DS were distinguished with an AUC of 0.95 (95% CI, 0.92-0.99). In this study, we demonstrate that plasma p-tau217 is highly accurate in detecting amyloid β positivity and predicting clinical progression in individuals with DS, outperforming other plasma biomarkers. These findings support its use as a reliable, noninvasive tool for early AD detection and management in individuals with DS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

The Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) and its contributions to understanding Alzheimer's disease in Down syndrome, A decade of discovery

  • Videla Toro, Laura|||0000-0002-9748-8465
  • Benejam, Bessy|||0000-0002-6789-8615
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Fernández, Susana|||0000-0002-9777-1156
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Arriola Infante, José Enrique|||0000-0002-3298-4601
  • Hoyo Soriano, Laura del|||0000-0003-4372-1599
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Estellés, Teresa
  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Aranha, Mateus|||0000-0001-9594-292X
  • Morcillo Nieto, Alejandra O.|||0000-0003-2202-3521
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Padilla, Concepción|||0000-0003-4102-6787
  • Valle-Tamayo, Natalia|||0000-0001-9322-3710
  • Sánchez-Aced, Érika|||0000-0001-7280-7493
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Sirisi Dolcet, Sonia|||0000-0002-5366-7832
  • Muñoz, Laia|||0000-0003-0578-3094
  • Torres Alcalá, Soraya|||0000-0002-7054-2046
  • Sánchez López, Oriol|||0000-0001-9405-1236
  • Garzón, Diana
  • Ribas, Laia
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Camacho, Valle|||0000-0003-0748-0847
  • Giménez, Sandra|||0000-0001-8031-2319
  • Delaby, Constance|||0000-0002-8606-6814
  • Belbin, Olivia|||0000-0002-6109-6371
  • Montal, Victor|||0000-0002-5714-9282
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Clarimón, Jordi|||0000-0002-6824-6942
  • González-Ortiz, Sofía|||0000-0003-2578-6671
  • Molina-Porcel, Laura|||0000-0003-4068-8578
  • Aldecoa, Iban|||0000-0001-5774-7453
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Videla, Sebastià
  • Blesa, Rafael|||0000-0003-4026-2884
  • Lleó, Alberto|||0000-0002-2568-5478
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Fortea, Juan|||0000-0002-1340-638X
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Sanjuan, Aída
  • Zsadanyi, Sara E.|||0000-0002-2033-5989
  • Franquesa-Mullerat, Maria|||0009-0006-1484-7132
  • Carreras, Mireia
  • Lorente, Oriol
  • Bounasr El Bennadi, Shaima El
  • Elbachiri, Sumia
  • Mota, Cecilia
  • Iulita, M. Florencia|||0000-0002-3360-4498
Down syndrome (DS) is a genetic form of Alzheimer's disease (AD) that offers crucial insights into AD pathogenesis. The Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) is a population-based multimodal biomarker cohort studying AD's natural history and clinical trials in DS. DABNI included 1135 participants (mean age 42.82, 46.3% female). At baseline, 673 participants were cognitively stable, 113 had prodromal AD, 239 had AD dementia, and 110 were uncertain due to non-AD conditions. Over 10 years, > 10000 clinical visits were conducted; follow-up showed that progression to symptomatic AD before age 40 was rare, but rates increased after age 50 (> 50% within 5 years). Neuropsychological and biomarker assessments demonstrated excellent diagnostic performance and a predictable sequence of changes, similar to autosomal dominant AD. DABNI participates in AD clinical trials and produced approximately 100 publications. The 10-year DABNI study provided critical insights into DS-associated AD (DSAD) and serves as a key platform for DS clinical trials. Highlights: Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) is a population-based multimodal cohort studying Alzheimer's disease in Down syndrome. Over 10 years, 1135 participants contributed to more than 10000 clinical visits and extensive biomarker studies. DABNI findings have transformed the understanding of Alzheimer's disease in Down syndrome, reinforcing its classification as a genetic form of the disease. The cohort integrates clinical care and research, enhancing early detection and patient management. DABNI supports clinical trials and has produced over 100 publications advancing Down syndrome-related Alzheimer's research.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Apolipoprotein E and Alzheimer's disease pathology in a diverse autopsy study

  • Suemoto, C.K.|||0000-0002-5942-4778
  • Paradela, Regina
  • Leite, Renata E. P.
  • Paes, Vitor R.
  • Pasqualucci, Carlos A.
  • Ferriolli, Eduardo
  • Zatz, Mayana|||0000-0003-3970-8025
  • do Nascimento Santos, Gabriel
  • de Alexandria, Marvin Afonso Longo Salvador
  • Pereira, Ana C.
  • Fortea, Juan|||0000-0002-1340-638X
  • Naslavsky, Michel
  • Grinberg, Lea T.
Apolipoprotein E allele 4 (APOE ε4) is the main genetic risk factor for late-onset Alzheimer's disease (AD), but most evidence comes from White populations in high-income countries. We investigated APOE and AD pathology in an ethnically diverse Brazilian autopsy cohort. This cross-sectional study used Biobank for Aging Studies (BAS) data. AD pathology was evaluated with Braak, Consortium to Establish a Registry for Alzheimer's Disease, and Thal criteria. APOE genotypes were obtained from blood or brain tissue. Regression models were adjusted for age, sex, race, and education; interaction with race was tested. Among 1391 participants (mean age 75.1 ± 12.4 years, 50% women, 64% White), APOE ε4showed a dose response with greater AD pathological burden and higher odds of AD diagnosis, while APOE ε2/X was protective. APOE ε4/ε4 did not show full penetrance across age groups. Associations were similar in White and Black individuals. APOE ε4was strongly associated with AD pathology, with consistent associations across racial groups. {'list': {'@list-type': 'bullet', '@id': 'alz70927-list-0001', 'list-item': [{'p': 'APOE ε4 increased AD neuropathological burden in Brazilians.'}, {'p': 'APOE ε2/εX was protective against AD pathology.'}, {'p': 'APOE ε4/ε4did not show full penetrance across age groups.'}, {'p': 'Associations between APOE and AD pathology were similar by race.'}, {'p': 'Large multiethnic autopsy study expands evidence beyond high-income country studies.'}]}}.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Plasma Phosphorylated Tau 217 to Identify Preclinical Alzheimer Disease

  • Janelidze, Shorena
  • Therriault, Joseph
  • Brum, Wagner S.
  • Pichet Binette, Alexa|||0000-0001-5218-3337
  • Stomrud, Erik
  • Palmqvist, Sebastian|||0000-0002-9267-1930
  • Teunissen, Charlotte E.|||0000-0002-4061-0837
  • van der Flier, Wiesje M.|||0000-0001-8766-6224
  • Rahmouni, Nesrine
  • Gispert, Juan Domingo|||0000-0002-6155-0642
  • Blennow, Kaj|||0000-0002-1890-4193
  • Doré, Vincent
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Fortea, Juan|||0000-0002-1340-638X
  • Villeneuve, Sylvia
  • Johnson, Sterling C.
  • Rosa-Neto, Pedro|||0000-0001-9116-1376
  • Petersen, Ronald C.
  • Schindler, Suzanne E.
  • Suárez Calvet, Marc|||0000-0002-2993-569X
  • Ossenkoppele, Rik
  • Hansson, Oskar|||0000-0001-8467-7286
  • Salvadó, Gemma
  • Bali, Divya
  • Orduña Dolado, Anna
  • Mattsson-Carlgren, Niklas
  • Coomans, Emma M.
  • Benzinger, Tammie L. S.
  • Feizpour, Azadeh
  • Rowe, Christopher C.
  • Jack Jr, Clifford R.|||0000-0001-7916-622X
Importance: Advances in Alzheimer disease (AD) have shifted research focus to earlier disease stages, necessitating more scalable approaches to identify cognitively unimpaired individuals with amyloid β (Aβ) pathology. Objective: To assess the utility of plasma phosphorylated tau 217 (p-tau217) for classifying Aβ status in cognitively unimpaired individuals, both as a stand-alone test and in a 2-step approach where positive plasma results were confirmed using a second modality (Aβ positron emission tomography [PET] or cerebrospinal fluid [CSF]). Design, Setting, and Participants: This cross-sectional cohort study used data collected between June 2009 and March 2024. We included 2916 cognitively unimpaired participants from 12 international independent observational cohorts in the US, Europe, Australia, and Canada with available plasma p-tau217 levels and CSF or PET Aβ biomarkers. Performance comparisons between mass spectrometry and immunoassay-based p-tau217 measurements were also performed (n = 964). Exposures: Plasma p-tau217 levels measured by immunoassay. Main Outcome and Measures: Aβ status, determined by CSF or Aβ PET biomarkers. Results: Participants had a mean (SD) age of 66.9 (9.9) years; 971 (33.3%) were Aβ positive by either CSF or PET, 1667 (57.2%) were women, and 1108 (38.1%) carried at least 1 APOE ϵ4 allele. As a stand-alone test, plasma p-tau217 achieved a positive predictive value (PPV) of 79% (95% CI, 74-84) and an overall accuracy of 81% (95% CI, 80-82). In a 2-step workflow, the PPV and accuracy significantly increased to 91% (95% CI, 86-95). While this approach required screening of 677 individuals with plasma p-tau217 to identify 100 Aβ-positive individuals, compared to 536 participants when using PET alone, it reduced the need for PET testing to 124. Immunoassays demonstrated comparable PPVs to mass spectrometry (80% [95% CI, 74-86] vs 85% [95% CI, 81-90]; P =.12) but significantly lower overall accuracy (82% [95% CI, 79-84]% vs 88 [95% CI, 86-90]; P <.001) and true Aβ-positive detection rate (49% [95% CI, 43-55] vs 69% [95% CI, 64-75]; P <.001). Conclusions and Relevance: The findings highlight the potential of plasma p-tau217 as a stand-alone test - or when used in a sequential 2-step approach alongside PET or CSF testing - as a cost-effective, scalable, and minimally burdensome strategy for identifying preclinical AD. Tailored screening workflows that incorporate p-tau217 can improve efficiency in participant selection for preclinical AD trials and, in the future, help guide access to disease-modifying treatments..
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

High-frequency oscillations >250 Hz in people with Down syndrome and associated Alzheimer's disease dementia

  • Lisgaras, Christos Panagiotis
  • Giménez, Sandra|||0000-0001-8031-2319
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Blessing, Esther
  • Fortea, Juan|||0000-0002-1340-638X
  • Osorio, Ricardo S.
INTRODUCTION: Alzheimer's disease (AD) dementia has near full penetrance in adults with Down syndrome (DS) and is strongly linked to late-onset myoclonic epilepsy in Down syndrome (LOMEDS). However, promising biomarkers of epileptogenicity, such as high-frequency oscillations (HFOs >250 Hz), have not been studied. This study is the first to use wideband polysomnography in DS to investigate if HFOs occurred and preceded AD dementia and LOMEDS. METHODS: Wideband (0.1 to 500 Hz, 2048 Hz) polysomnography was performed using the international 10-20 system. HFOs were automatically detected during slow-wave sleep, followed by manual review. RESULTS: Fourteen individuals with DS and five age-matched euploid controls were studied, with all DS cases showing HFOs. HFOs emerged before AD dementia and LOMEDS and showed hemispheric lateralization in asymptomatic but not symptomatic AD dementia cases. A trend toward increasing HFO rates with age in DS warrants further confirmation. DISCUSSION: HFOs are promising biomarkers that may predict symptomatic AD dementia in adults with DS. Highlights: Wideband polysomnography reveals a new electrical abnormality in DS. HFOs precede AD dementia in DS. The occurrence of HFOs in DS is independent of an epilepsy diagnosis. HFOs showed hemispheric lateralization in asymptomatic DS cases. A trend of increased HFO rate with advancing age warrants further investigation.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clinical Impact and Prognostic Value of Alzheimer Disease Biomarkers in the Very Old

  • Ceriello, Chiara
  • Torres Bonafonte, Olga H.|||0000-0002-0305-8211
  • Rubio Guerra, Sara|||0000-0001-7652-8029
  • Garcia Castro, Jesús|||0000-0003-1503-4775
  • Selma Gonzalez, Judit|||0009-0006-1021-4653
  • Sala Matavera, Isabel|||0000-0002-9886-4792
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Vera-Campuzano, Elena
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Álvarez-Sánchez, Esther|||0009-0002-8760-2153
  • Lorente, Oriol
  • Carreras, Mireia
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Belbin, Olivia|||0000-0002-6109-6371
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
Background and Objectives: Alzheimer disease (AD) is increasingly viewed as a clinical-biological continuum, but the utility of biomarkers in individuals aged ≥80 years, the so-called “very old,” remains uncertain, because of concerns about its clinical usefulness. This study aimed to determine the clinical impact and prognostic value of AD biomarkers in very old individuals. Methods: We performed a retrospective longitudinal cohort study within the Sant Pau Initiative on Neurodegeneration (SPIN, Barcelona, Spain), a memory clinic–based research cohort. Patients were referred from primary care physicians or community neurologists for evaluation within a public universal health care catchment area. We included SPIN participants evaluated between October 2013 and May 2024 who were aged ≥80 years and had mild cognitive impairment (MCI) at the baseline visit. Participants underwent standardized clinical and neuropsychological assessments and had CSF and plasma biomarker measurements available. AD biology was defined by the CSF phosphorylated tau at threonine 181/amyloid-β 42 ratio. Plasma phosphorylated tau at threonine 217 (p-Tau217) was evaluated for (1) diagnostic accuracy for AD biology and (2) prognostic associations with longitudinal cognitive change (Mini-Mental State Examination [MMSE]) and progression to dementia. Analyses used linear mixed-effects models for MMSE trajectories and Cox regression for dementia conversion. Results: A total of 167 participants were included (mean age 82.3 years, 59% women) with a mean follow-up of 35.8 months; the ones with AD biology (n = 116, 69%) had worse baseline cognitive performance, particularly in memory, compared with those without (Cohen d = 0.34, p = 0.03). Plasma p-Tau217 showed excellent diagnostic accuracy for detecting AD biology (0.93, 95% CI 0.88–0.98; cutoff 0.19 pg/mL; sensitivity 94.5%; specificity 84%). Over time, participants with AD biology declined faster on the MMSE than those without (−0.47 vs −0.18 points per year; p < 0.01). Cox models showed an increased risk of progression to a dementia stage among individuals with higher plasma p-Tau217 concentrations (hazard ratio 1.49, 95% CI 1.05–2.13, p = 0.026). Discussion: In very old individuals with MCI, AD biology (CSF) and plasma p-Tau217 identify individuals at higher risk of faster cognitive decline and progression to dementia. Limitations of this study include the single-center design and the modest sample size.